FSD Pharma Inc. (HUGE): Price and Financial Metrics
HUGE Price/Volume Stats
| Current price | $1.25 | 52-week high | $2.10 |
| Prev. close | $1.37 | 52-week low | $0.62 |
| Day low | $1.24 | Volume | 282,100 |
| Day high | $1.36 | Avg. volume | 158,390 |
| 50-day MA | $1.27 | Dividend yield | N/A |
| 200-day MA | $1.26 | Market Cap | 48.80M |
HUGE Stock Price Chart Interactive Chart >
FSD Pharma Inc. (HUGE) Company Bio
FSD Pharma Inc., through its subsidiary, FV Pharma Inc., produces medical cannabis in Canada. The company focuses on the development of indoor grown pharmaceutical grade cannabis; and research and development of various cannabinoid-based treatments for central nervous system disorders and autoimmune diseases of the skin, GI tract, and musculoskeletal system, such as chronic pain. FSD Pharma Inc. has strategic alliance agreements with SciCann Therapeutics Inc., CannTab Therapeutics, and Solarvest BioEnergy Inc. The company was founded in 1998 and is headquartered in Toronto, Canada.
Latest HUGE News From Around the Web
Below are the latest news stories about FSD PHARMA INC that investors may wish to consider to help them evaluate HUGE as an investment opportunity.
InvestmentPitch Media Video Discusses FSD Pharma’s Continued Development of its Exciting New Rapid Detox Drink UNBUZZD™, with Video Comments from Kevin HarringtonVANCOUVER, British Columbia, Sept. 22, 2023 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a biotechnology company building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, continues with the development of its exciting new rapid detox drink UNBUZZD™. Today, we’re following up on our August 2nd feature video in which we discussed UNBUZZD™, a proprietary formulation of natural |
FSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis; The Report Shows Compound to be Safe and Well ToleratedFSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, today announced that an interim report has been received for the first-in-human ("FIH") single ascending dose Phase I clinical trial evaluating the Company's novel drug candidate Lucid-21-302 |
FSD Pharma Announces Analyst Coverage Initiated by Singular ResearchFSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, today announced that Singular Research has initiated analyst coverage on FSD Pharma. |
FSD Pharma Rebuts Claims of GBB Drink Lab now acquired by Jupiter Wellness Inc. Trading under the symbol (NASDAQ: JUPW)TORONTO, August 25, 2023--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, today provides clarity and rebuttal to frivolous claims disparaging the Company and its groundbreaking efforts relating to its development of an innovative rapid alcohol detoxification drink, using its pro |
FSD Pharma Selected to Present its Phase 1 Data on Lucid-MS at MSMilan 2023 – 9th Joint ECTRIMS-ACTRIMS Meeting for October 11-13, 2023/ FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, is pleased to announce that its late breaking abstract about Phase 1 first-in-human data on Lucid-MS (Lucid-21-302) was selected for presentation at the upcoming MSMilan 2023 - 9th Joint |
HUGE Price Returns
| 1-mo | 5.04% |
| 3-mo | -5.30% |
| 6-mo | -20.38% |
| 1-year | 50.60% |
| 3-year | -52.83% |
| 5-year | -99.01% |
| YTD | 58.55% |
| 2022 | -22.71% |
| 2021 | -34.62% |
| 2020 | -71.26% |
| 2019 | -87.37% |
| 2018 | 755.60% |
Loading social stream, please wait...